Resminostat Improves Survival in Hepatocellular Carcinoma

With positive overall survival data from a Phase II trial in hand, 4SC AG aims to move its pan-histone deacetylase inhibitor (HDAC) resminostat into a pivotal Phase III trial in second-line hepatocellular carcinoma (HCC) in the first half of next year.

To continue reading subscribe now to BioWorld Asia (formerly International)